Wall St Engine
CHINA VOWS TO TAKE MEASURES IF US INSISTS ON GOING ITS OWN WAY
tweet
CHINA VOWS TO TAKE MEASURES IF US INSISTS ON GOING ITS OWN WAY
CHINA 🇨🇳 ISSUES STATEMENT ON US ADJUSTING CHIP EXPORT CONTROLS
CHINA SAYS US UNDERMINES CONCENSUS REACHED IN GENEVA TALKS
CHINA ASKS US TO 'CORRECT WRONGDOINGS' tweet
twitter.com
undefined
undefined
Offshore
Photo
Wall St Engine
S&P 500 Opening Bell Heatmap (May 19, 2025)
$SPY -0.92% 🟥
$QQQ -1.25% 🟥
$DJI -0.64% 🟥
$IWM -1.42% 🟥 https://t.co/b05lSdyqXG
tweet
S&P 500 Opening Bell Heatmap (May 19, 2025)
$SPY -0.92% 🟥
$QQQ -1.25% 🟥
$DJI -0.64% 🟥
$IWM -1.42% 🟥 https://t.co/b05lSdyqXG
tweet
Offshore
Photo
Quiver Quantitative
How is this even possible?
Representative John McGuire just filed a single stock trade, his first trade ever.
It was an April 10th purchase of UnitedHealth.
He sits on a House Subcommittee on Health Care.
The stock has fallen 48% since his purchase.
Look at this graph... https://t.co/erePZk88MM
tweet
How is this even possible?
Representative John McGuire just filed a single stock trade, his first trade ever.
It was an April 10th purchase of UnitedHealth.
He sits on a House Subcommittee on Health Care.
The stock has fallen 48% since his purchase.
Look at this graph... https://t.co/erePZk88MM
tweet
Wall St Engine
NIPPON STEEL PITCHES $14B U.S. INVESTMENT TO SAVE U.S. STEEL $X DEAL
Nippon Steel is offering to invest $14B into U.S. Steel, including up to $4B for a new mill, if the Trump admin clears its takeover. The plan boosts its original $1.4B pledge and includes $11B through 2028—$1B of that for a greenfield site expected to grow to $4B.
The deal faces a May 21 national security review deadline. Biden previously blocked the merger; Trump has 15 days after the review to make a call. Nippon’s pushing hard to close the deal, with a $565M breakup fee and 25% steel tariffs at stake.
tweet
NIPPON STEEL PITCHES $14B U.S. INVESTMENT TO SAVE U.S. STEEL $X DEAL
Nippon Steel is offering to invest $14B into U.S. Steel, including up to $4B for a new mill, if the Trump admin clears its takeover. The plan boosts its original $1.4B pledge and includes $11B through 2028—$1B of that for a greenfield site expected to grow to $4B.
The deal faces a May 21 national security review deadline. Biden previously blocked the merger; Trump has 15 days after the review to make a call. Nippon’s pushing hard to close the deal, with a $565M breakup fee and 25% steel tariffs at stake.
tweet
Wall St Engine
$JPM CFO Jeremy Barnum says full-year net interest income could come in “a little better, maybe by a billion dollars” vs prior expectations, though the current $94.5B guidance stands for now.
He added, “the yield curve’s been very volatile… we’d like to see things settle down before sharpening our pencils.”
JPM also flagged potential tariff impact on its commercial book, saying it depends on how much cost gets passed through. Trading remains a bright spot, and the firm is sticking with its current headcount, asking leaders to “leverage the existing footprint” to support growth.
tweet
$JPM CFO Jeremy Barnum says full-year net interest income could come in “a little better, maybe by a billion dollars” vs prior expectations, though the current $94.5B guidance stands for now.
He added, “the yield curve’s been very volatile… we’d like to see things settle down before sharpening our pencils.”
JPM also flagged potential tariff impact on its commercial book, saying it depends on how much cost gets passed through. Trading remains a bright spot, and the firm is sticking with its current headcount, asking leaders to “leverage the existing footprint” to support growth.
tweet
Offshore
Photo
Wall St Engine
$REGN TO BUY 23ANDME OUT OF BANKRUPTCY FOR $256M
Regeneron is acquiring 23andMe for $256M, taking control of millions of customers’ genetic data as part of the deal. The move raises privacy concerns, but Regeneron says it’ll stick to 23andMe’s existing privacy policies and legal standards.
The deal includes the company’s Personal Genome Service, research services, and biobank. All consumer-facing services will continue, and the company plans to explain its data use plans to a court-appointed ombudsman. The deal is set to close in Q3.
tweet
$REGN TO BUY 23ANDME OUT OF BANKRUPTCY FOR $256M
Regeneron is acquiring 23andMe for $256M, taking control of millions of customers’ genetic data as part of the deal. The move raises privacy concerns, but Regeneron says it’ll stick to 23andMe’s existing privacy policies and legal standards.
The deal includes the company’s Personal Genome Service, research services, and biobank. All consumer-facing services will continue, and the company plans to explain its data use plans to a court-appointed ombudsman. The deal is set to close in Q3.
tweet
Offshore
Photo
Wall St Engine
Salesforce $CRM is cutting prices on its Slack app for federal agencies, offering discounts as high as 90% through November, per the GSA. It’s part of a broader push by the Trump administration to cut tech costs and centralize federal software deals under the “OneGov” program.
The GSA says it aims to lock in longer-term contracts and ditch agency-by-agency pricing. Salesforce joins Google and Adobe, who’ve also recently offered federal discounts. Interoperability and direct purchases from vendors — not resellers — are key to the strategy.
tweet
Salesforce $CRM is cutting prices on its Slack app for federal agencies, offering discounts as high as 90% through November, per the GSA. It’s part of a broader push by the Trump administration to cut tech costs and centralize federal software deals under the “OneGov” program.
The GSA says it aims to lock in longer-term contracts and ditch agency-by-agency pricing. Salesforce joins Google and Adobe, who’ve also recently offered federal discounts. Interoperability and direct purchases from vendors — not resellers — are key to the strategy.
tweet
Wall St Engine
$MNMD | FDA Commissioner Marty Makary says exploring psychedelics like psilocybin and ibogaine is now a top priority, especially to help veterans dealing with PTSD and traumatic brain injuries from “unnecessary wars.” He’s pushing for a faster path to approval, saying the agency must “cut red tape” and act on data quickly.
Makary emphasized that while the FDA isn’t endorsing any one treatment yet, they’re listening to doctors and patients who say these therapies work. He stressed the need for “expeditious and rapid review” once trials read out.
tweet
$MNMD | FDA Commissioner Marty Makary says exploring psychedelics like psilocybin and ibogaine is now a top priority, especially to help veterans dealing with PTSD and traumatic brain injuries from “unnecessary wars.” He’s pushing for a faster path to approval, saying the agency must “cut red tape” and act on data quickly.
Makary emphasized that while the FDA isn’t endorsing any one treatment yet, they’re listening to doctors and patients who say these therapies work. He stressed the need for “expeditious and rapid review” once trials read out.
tweet